Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.

导出 OA

翻译打印收藏纠错

第一作者： Jonathan,Mauer

第一单位： Pfizer, New York, NY, USA.

作者： Jonathan,Mauer ^[1] ; Kristin,Bullok ^[2] ; Stephen,Watt ^[1] ; Ed,Whalen ^[1] ; Leo,Russo ^[1] ; Rod,Junor ^[1] ; John,Markman ^[3] ; Brett,Hauber ^[1] ; Tommi,Tervonen ^[4]

作者单位： Pfizer, New York, NY, USA. ^[1] Eli Lilly & Co., Global Patient Safety, Indianapolis, IN, USA. ^[2] Translational Pain Research Program, Department of Neurosurgery, University of Rochester, Rochester, NY, USA. ^[3] CHOICE Institute, University of Washington School of Pharmacy, Seattle, WA, USA. ^[4] Evidera, London, UK. ^[5]

关键词 benefit-risk assessment nerve growth factor inhibitor opioid osteoarthritis patient preference

主题词消炎药, 非甾类(Anti-Inflammatory Agents, Non-Steroidal);人类(Humans);阿片相关性障碍(Opioid-Related Disorders);骨关节炎(Osteoarthritis);随机对照试验(主题)(Randomized Controlled Trials as Topic);危险性评估(Risk Assessment)

DOI 10.1111/bcp.15309

PMID 35277997

发布时间 2022-10-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交